Expertise

Maneesh Gupta

Senior Partner

Expertise:

Brand Plan Development, Commercialization, Consulting (Strategy Management & Regulatory), Forecasting Activities, Oncology, Product Launch

Maneesh comes to EVERSANA Management Consulting from IQVIA. He held a number of leadership roles over his 10 years at the firm, most recently serving as Practice Lead, Launch Excellence and Brand and Commercial Strategy. In this role, he led the launch excellence and brand strategy practice in the United States, focusing on helping clients optimize their strategy, planning, implementation, and tracking. Among his many accomplishments, Maneesh conceptualized and developed IQVIA’s patient centricity/patient journey offering from scratch, developing a $6 million business from the offering within three years.

Prior to IQVIA, Maneesh was Manager at ZS Associates, where he led and managed strategy, marketing, and sales consulting projects for pharmaceutical and biotech clients. Before that, he was a Consultant at DuPont Consulting Solutions, working on marketing and sales effectiveness projects. He also worked with the new product development team at DuPont Titanium Technologies.

As Lead, Practicum Team, at IBM, Maneesh developed a strategy for Websphere Connectivity, leading a team of four MBAs, and as Marketing and Sales Operations Manager at Aricent Technologies (Futuresoft), he managed a team across the brand, sales effectiveness, and marketing functions. His career began at Thomson Consumer Electronics in Chennai, India, where Maneesh was an Assistant Product Manager.

Maneesh holds an MBA in business administration from The University of North Carolina at Chapel Hill and an MBA in marketing and supply chain management from UNC Kenan-Flagler Business School. He earned his bachelor of chemical engineering from Jadavpur University in Calcutta, India.

Articles by Maneesh Gupta

Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency

  In an EVERSANA-led discussion, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key Challenges: 3x lower net revenue than experienced launchers $247M average launch cost 24-month prep timeline 78% of small-cap companies face delays or rejections […]

Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency

In an EVERSANA-led discussion, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key Challenges: 3x lower net revenue than experienced launchers $247M average launch cost 24-month prep timeline 78% of small-cap companies face delays or rejections Solutions […]

Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency

In a recent EVERSANA webinar, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key challenges: 3x lower net revenue than experienced launchers $247M average launch cost 24-month prep timeline 78% of small-cap companies face delays or rejections […]

Whitepaper: Transformative Commercialization for New BioPharma Entrants
Transformative Commercialization for New Biopharma Entrants: Ensuring Success With Capital and Time Efficiency

Discover the transformative power of EVERSANA’s innovative commercialization model in this white paper. This essential guide is ideal for pharmaceutical companies, particularly first-time launchers, aiming to navigate the complexities of product commercialization. It addresses the major challenges faced by new entrants in the biopharma sector and provides actionable insights to overcome them. Learn how EVERSANA’s […]

Overcoming the Commercialization Challenges of Personalized Cancer Immunotherapies

Personalized cancer immunotherapies are emerging as a revolutionary approach to cancer treatment, aiming to provide individualized therapies based on a patient’s specific genetic makeup. The FDA has not yet approved any personalized cancer immunotherapies, creating an intense race within pharma to be the first mover.   These therapies have the potential to overcome the limitations of […]

Interested in scheduling a meeting or speaking event?

Contact Us